Since the last edition of this book, major advances have been made in our understanding of key pathways that control tumor progression. This has led to the development of new anticancer agents that have the ability to block the activity of proteins involved in neoplastic cell development and proliferation. Targeted Therapies in Oncology, Second Edition provides a concise timely panorama of existing targeted therapies and progress into future anticancer treatments. These therapies notably include: Targeted agents of immune checkpoints Signal-transduction inhibitors Antiangiogenic agents Vascular-disrupting agents Apoptosis modulators Stem cell inhibitors Tumor profiling for drug development The book emphasizes the biology behind this new class of drugs as well as the clinical achievements obtained. The contributors to this volume stand at the cutting edge of cancer research and treatment around the world.Similarly, in advanced non-small-cell lung cancer (NSCLC), a randomized phase II first-line study of maintenance tremelimumab after four cycles of ... Ipilimumab ( MDX-010, Yervoy; Bristol-Myers Squibb) is a fully human IgG1 mAb that binds to CTLA-4 blocking its interaction with B7 molecules on antigen presenting cells.42 In March 2011, ipilimumab was approved by the FDA for the treatment ofanbsp;...
|Title||:||Targeted Therapies in Oncology, Second Edition|
|Author||:||Giuseppe Giaccone, Jean-Charles Soria|
|Publisher||:||CRC Press - 2013-10-21|